Episodes
-
In this episode, Caitlin Costello, MD, discusses important topics related to relapsed/refractory (R/R) multiple myeloma (MM), including:
3 bispecific antibodies approved for the treatment of R/R MM that target BCMA or GPRC5DThe role of bispecific antibodies in R/R MMSafety considerations for patients while receiving a bispecific antibodyEmerging data and clinical trials with bispecific antibodiesKey clinical pearls for optimal use of bispecific antibodies
Presenter:Caitlin Costello, MD
Clinical Professor of Medicine
Director, Multiple Myeloma Program
Division of Blood and Marrow Transplantation
Moores Cancer Center
UC San Diego
La Jolla, CaliforniaLink to full program:
https://bit.ly/40bjFCZ -
In this episode, Thor R. Halfdanarson, MD, and Jonathan Strosberg, MD, discuss important topics related to gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including:
The diagnosis and typical presenting symptoms of GEP-NETsFindings from recent key phase III studies including NETTER-2 and CABINETRecommendations for treatment sequencingNotable clinical pearls regarding GEP-NET therapiesCurrent guidelines for GEP-NET care and monitoring
Presenters:Thor R. Halfdanarson, MD
Consultant, Division of Medical Oncology
Professor of Oncology
Associate Professor of Medicine
Mayo Clinic Comprehensive Cancer Center
Chair, Hepato-Pancreatico-Biliary Disease Group
Rochester, MinnesotaJonathan Strosberg
Professor, GI Oncology
Chair, Neuroendocrine Tumor Division
Moffitt Cancer Center and Research Institute
Tampa, FloridaLink to full program:
https://bit.ly/3Y0JWBa -
Missing episodes?
-
In this episode, listen to Ana Oaknin, MD, PhD and Alexandra Leary, MD, PhD, share their clinical insights and takeaways on key updates and new data presented for ovarian, endometrial, and cervical cancer at the ESMO 2024 annual congress including:
Phase III PRIMA/ENGOT-OV26/GOG-3012 Final OS Results: Niraparib as First-Line Maintenance in Advanced Ovarian CancerATHENA COMBO/GOG-3020/ENGOT-ov45: Rucaparib With or Without Nivolumab Maintenance in Newly Diagnosed Ovarian CancerPhase II PICCOLO Trial of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive Ovarian Cancer With High-FRα ExpressionPhase III KEYNOTE-B21/GOG-3053 Study of Adjuvant Chemotherapy With or Without Radiotherapy With or Without Pembrolizumab in Patients With Newly Diagnosed Endometrial Cancer or Carcinosarcoma After Curative Surgery With no Residual DiseasePhase III KEYNOTE-A18 Overall Survival Results: Pembrolizumab Plus Concurrent Chemoradiation in High-Risk Locally Advanced Cervical Cancer
Program faculty:
Ana Oaknin, MD, PhD
Head of Gynaecologic Cancer Programme
Department of Medical Oncology
Vall d’ Hebron University Hospital
Vall d’Hebron Institute of Oncology
Barcelona, SpainAlexandra Leary, MD, PhD
Co-Director, Department of Medical Oncology
Medical Oncologist, Gynecology
Team Leader, Gynecologic Translational Research Lab,
Institut Gustave Roussy
Paris, FranceResources:
To download the slides associated with this podcast discussion, please visit the program page. -
In this episode, listen to Matthew S. Davids, MD, MMSc, and Lindsey Roeker, MD, discuss BTK inhibitor resistance and how it shapes treatment choices for patients with CLL, including:
Contemporary treatment paradigms for patients with CLLSafety and efficacy of current regimensMolecular testing, including when and how to test for BTK inhibitor resistanceConsidering BTK inhibitor resistance when sequencing therapyProgram faculty:
Matthew S. Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Leader, Lymphoma Program
Dana-Farber/Harvard Cancer Center
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, MassachusettsLindsey Roeker, MD
Assistant Attending
CLL Program Director
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New YorkResources:
To review a CME-certified text activity and download slides associated with this podcast discussion, please visit the program page. -
In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available and emerging clinical data for second-line and beyond treatments in patients with recurrent ROS1-altered advanced NSCLC including:
Assessing ROS1-TKI resistance mutations with tumor and liquid biopsies in patients with ROS1-altered advanced NSCLCPrevious TKI-treated cohort from the TRIDENT-1 study: efficacy of repotrectinib in patients with recurrent ROS1-altered NSCLC and measurable baseline brain metastases Phase II TRUST-1 trial of taletrectinib: activity in patients with known ROS1 G2032R resistance mutation ROS1-altered advanced NSCLCThe global phase I/II ARROS-1 study of zidesamtinib (NVL-520): safety summary in patients with ROS1-altered advanced NSCLC
Program faculty:
Jessica J. Lin, MD
Attending Physician
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, MassachusettsAlice T. Shaw, MD, PhD
Chief, Strategic Partnerships
Attending Physician, Thoracic Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MassachusettsResources:
To download the slides associated with this podcast discussion, please visit the program page. -
In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available clinical data in support of frontline treatments for ROS1-altered NSCLC including:
Efficacy and safety data for crizotinib, entrectinib, and repotrectinib in patients with ROS1-altered advanced NSCLCLong-term safety observations for crizotinib and entrectinib CNS activity of entrectinib and repotrectinib in patients with brain metastasesRepotrectinib activity in ROS1-TKI resistance mutations
Program faculty:
Jessica J. Lin, MD
Attending Physician
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, MassachusettsAlice T. Shaw, MD, PhD
Chief, Strategic Partnerships
Attending Physician, Thoracic Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MassachusettsResources:
To download the slides associated with this podcast discussion, please visit the program page. -
In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the current understanding of ROS1 rearrangements in non-small-cell lung cancer tumor biology and its implications for molecular testing and treatment selection including:
ROS1-gene fusions in advanced lung cancerROS1 testing recommendations with DNA NGS, RNA NGS, FISH break apart assay, and IHCComparative specificity of ROS1 and ALK targeting tyrosine kinase inhibitorsAdvantages of RNA- vs DNA-based next-generation sequencing
Program faculty:
Jessica J. Lin, MD
Attending Physician
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, MassachusettsAlice T. Shaw, MD, PhD
Chief, Strategic Partnerships
Attending Physician, Thoracic Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MassachusettsResources:
To download the slides associated with this podcast discussion, please visit the program page
-
In this episode, listen to Floor J. Backes, MD, and Angeles Alvarez Secord, MD, MHSc, share their clinical insights and takeaways on new data presented for endometrial, ovarian, and cervical cancers presented at the 2024 annual meetings of the Society of Gynecologic Oncology and American Society of Clinical Oncology including:
RUBY Part 1 Subgroup Analyses by MRR Status: Addition of dostarlimab to platinum-based therapy followed by dostarlimab maintenance in advanced endometrial cancerRUBY Part 2: Survival outcomes with addition of dostarlimab to platinum-based therapy followed by dostarlimab plus niraparib maintenance in advanced endometrial cancerSurvival Analyses From Phase III NRG GY018: Carboplatin plus paclitaxel with or without pembrolizumab as frontline treatment for patients with advanced endometrial cancerDUO-E: First-line therapy with carboplatin plus paclitaxel plus bevacizumab and durvalumab followed by maintenance with bevacizumab, durvalumab, and olaparib in newly diagnosed endometrial cancerLong-term Follow-up From SIENDO: PFS in TP53 wild-type and preliminary survival by molecular subgroups in patients with endometrial cancer and complete or partial response after ≥12 weeks of first line taxane/carboplatinSubgroup Analyses From the Randomized Phase III MIRASOL: Mirvetuximab soravtansine vs investigator’s choice of chemotherapy in FR𝝰-high platinum-resistant ovarian cancerSubgroup Analyses of Raludotatug Deruxtecan (R-DXd): An anti-CDH6 antibody–drug conjugate in previously treated ovarian cancerPhase III CARACO Trial: Omission of lymphadenectomy in advanced ovarian cancer treated with interval cytoreductive surgery after neoadjuvant chemotherapyinnovaTV 301/ENGOT-cx12/GOG-3057: Tisotumab vedotin vs investigator’s choice of chemotherapy in patients with advanced cervical cancerRandomized, Double-blind, Placebo-controlled Phase III Trial: Addition of pembrolizumab to concurrent chemoradiation in high-risk locally advanced cervical cancerProgram faculty:
Floor J. Backes, MD
Professor
Director of Clinical Research
Division of Gynecologic Oncology
Associate Fellowship Director
Department of Obstetrics and Gynecology
The Ohio State University College of Medicine
The James Cancer Hospital and Solove Research Institute
Columbus, OhioAngeles Alvarez Secord, MD, MHSc
Professor of Obstetrics & Gynecology
Division of Gynecologic Oncology
Director, Gynecologic Oncology Clinical Trials
Associate Director, Clinical Research, Gynecologic Oncology Program
Duke Cancer Institute
Duke University Medical Center
Durham, North CarolinaResources:
To download the slides associated with this podcast discussion, please visit the program page. -
In this episode, Dr Virginia Kaklamani moderates a discussion with Dr Aditya Bardia and Dr Sarah Sammons answering audience questions on the latest data on the use of oral SERDs therapy, including how to incorporate this new class of therapy into treatment plans for patients with HR+/HER2- breast cancer.
Presenters:
Virginia Kaklamani, MD, DSc
Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
A.B. Alexander Distinguished Chair in Oncology Leader
Breast Oncology Program
UT Health San Antonio
MD Anderson Cancer Center
San Antonio, TexasAditya Bardia, MD, MPH, FASCO
Professor of Medicine
Geffen School of Medicine at UCLA
Director, Breast Oncology Program
Assistant Chief (Translational Research)
Division of Medical Oncology
Director of Translational Research Integration
UCLA Health Jonsson Comprehensive Cancer Center
Los Angeles, CaliforniaSarah Sammons, MD
Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MassachusettsLink to full program:
https://bit.ly/46hLGcM -
In this podcast episode, Farrukh Awan, MD, Jeremy S. Abramson, MD, MMSc, and Shuo Ma, MD, PhD, discuss real-world patient cases and how to align current clinical practice with the NCCN guidelines for CLL/SLL, including:
Prognostic variables when deciding between regimensRole of MRD in CLLResults from the phase II CAPTIVATE trialChoosing among the available covalent BTK inhibitorsPreferred partner anti-CD20 antibody in CLL/SLLRole of the noncovalent BTK inhibitor, pirtobrutinib, in CLL/SLLUse of CAR T-cell therapy in CLL/SLL
Presenters:Farrukh Awan, MD
Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, TexasJeremy S. Abramson, MD, MMSc
Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, MassachusettsShuo Ma, MD, PhD
Professor of Medicine
Division of Hematology-Oncology
Department of Medicine
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Feinberg School of Medicine
Chicago, IllinoisContent based on an online CME program supported by educational grants from BeiGene; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Lilly, and an independent medical education grant from AbbVie.
Link to full program:
https://bit.ly/3LzA2As -
In this episode, listen to Dr Brady L. Stein share his clinical insights and takeaways on new data for myeloproliferative neoplasms (MPNs) presented at the 2024 ASCO Annual Meeting and the EHA 2024 Congress including:
Long-term survival adjusted for treatment crossover in patients with myelofibrosis (MF) treated with momelotinib vs danazol in the MOMENTUM trialEfficacy of pacritinib in patients with MF who have both thrombocytopenia and anemiaUpdated safety and efficacy data from the phase III MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor–naive MFImpact of spleen volume on post-allogenic hematopoietic transplant outcomes in patients with MF: utility of 3D volumetrics in splenomegalyProgression to MF in patients with essential thrombocythemia: an analysis from the prospective MOST studyJAK2V617F molecular response correlates with event-free survival in a patient population with early polycythemia veraPhase III TRANSFORM-1 study: efficacy and safety of navitoclax combined with ruxolitinib vs ruxolitinib plus placebo in patients with untreated MFPatient characteristics, treatment patterns, and health outcomes in a real-world population of patients with MF treated with fedratinibProgram faculty:
Brady L. Stein, MD, MHS
Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, IllinoisResources:
To download the slides associated with this podcast discussion, please visit the program page. -
In this podcast episode, Julio C. Chavez, MD, MS, and Alan Skarbnik, MD, discuss the emerging role of CELMoDs in NHL care, including:
Rationale for targeting CELMoDs in NHLMechanism of action of CELMoDsKey studies and available efficacy and safety data with investigational CELMoDs in NHLKey ongoing clinical trials of CELMoDs in NHLStrategies to boost NHL clinical trial diversity among underserved communitiesPresenters:
Julio C. Chavez, MD, MS
Associate Member
Department of Malignant Hematology
ICE-T Clinical Research Medical Director for Hematologic Malignancies
H. Lee Moffitt Cancer Center and Research Institute
Associate Professor
University of South Florida
Tampa, FloridaAlan Skarbnik, MD
Director, Lymphoma and CLL Program
Director, Immune Effector Cell Therapeutics Program
Novant Health Cancer Institute
Charlotte, North CarolinaContent based on an online CME program supported by educational grants from Bristol-Myers Squibb.
Link to full program:
https://bit.ly/45YXoZI -
In this episode, Dr Joyce O’Shaughnessy moderates a discussion with Dr Sara Hurvitz and Dr Erica Mayer answering audience questions on the latest data on incorporating CDK4/6 inhibitors into treatment plans for patients with HR+/HER2- breast cancer. Topics in this podcast include:
Evidence from the monarchE and NATALEE trials of adjuvant abemaciclib and ribociclib, respectively in HR+/HER2- high-risk early breast cancerFactors used to assess risk of recurrence in early breast cancer, including the role of Ki-67 expressionDetermining the need for adjuvant chemotherapy and selection of chemotherapy agentsSelection of patients who may benefit from the addition of adjuvant CDK4/6 inhibitor therapy with endocrine therapyPotential use of preoperative CDK4/6 inhibitorsSequencing therapy for patients with high-risk early breast cancer and a germline BRCA mutationOverview of first-line therapy for advanced HR+/HER2 breast cancerExpert opinion on selection of first-line therapy and factors to considerSelection of second-line therapy based on mutational analysis and recent data from the post-MONARCH trialPresenters:
Joyce O’Shaughnessy, MD
Celebrating Women Chair in
Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Sarah Cannon Research Institute
Texas Oncology
Dallas, TexasSara A. Hurvitz, MD, FACP
Professor of Medicine
Head, Division of Hematology and Oncology
Department of Medicine, UW Medicine
Senior Vice President
Clinical Research Division
Fred Hutchinson Cancer Center
Seattle, WashingtonErica L. Mayer, MD, MPH
Director of Breast Cancer Clinical Research
Institute Physician
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MassachusettsLink to full program:
https://bit.ly/3XZKp8f -
In this episode, listen to Professor Eunice S. Wang, MD, share her clinical insights and takeaways on new data for acute myeloid leukemia (AML) presented at the 2024 ASCO annual meeting and the EHA 2024 Congress including:
Data from the prospective, single-center phase Ib/II study of FLAG-IDA plus venetoclax in newly diagnosed or relapsed/refractory AML Phase I/II study of oral decitabine/cedazuridine with venetoclax and gilteritinib in patients with newly diagnosed and relapsed/refractory FLT3-mutant AMLA retrospective comparison of abbreviated course 7+7 vs standard HMA plus venetoclax doublet in older/unfit patients with newly diagnosed AML Multisite randomized trial of a collaborative palliative and oncology care model for patients with AML and myelodysplastic syndromes (MDS) receiving nonintensive therapyFinal 5-year results from the phase II pivotal cohort of olutasidenib for IDH1-mutated AML Post hoc analyses of outcomes in patients with AML and MDS-related changes who received oral azacitidine maintenance therapy in the phase III QUAZAR AML-001 studyFirst-in-human phase I/II of the menin-MLL inhibitor DSP-5336 in patients with R/R acute leukemia: updated results from the dose escalation phase A phase Ib study of the menin-KMT2A inhibitor bleximenib in combination with venetoclax and azacitidine in R/R AML with alterations in KMT2A or NPM1Program faculty:
Eunice S. Wang, MD
Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New YorkCourtney DiNardo, MD, MSCE
Professor of Medicine
Department of Leukemia
MD Anderson Cancer Center
Houston, TexasResources:
To download the slides associated with this podcast discussion, please visit the program page:
https://bit.ly/4bvJGij -
In this episode, listen to Professor Courtney DiNardo, MD, MSCE, share her clinical highlights and clinical takeaways on new data for myelodysplastic syndromes (MDS) presented at the 2024 ASCO annual meeting and the EHA 2024 Congress including:
COMMANDS trial of luspatercept in transfusion-dependent, erythropoietin stimulating agent–naive, very low–, low- or intermediate-risk MDSReal-world dose-escalation and outcomes among patients with lower-risk MDS receiving luspatercept in clinical practicePhase II ASTREON trial―preliminary safety/efficacy of oral azacitidine in low-/intermediate, intermediate-risk, MDSPhase III IMerge: overall survival and transfusion independence with imetelstat in patients with low-risk or intermediate-1–risk MDS Phase III ENHANCE study of magrolimab plus azacitidine vs azacitidine plus placebo for higher-risk MDS Oral decitabine/cedazuridine plus venetoclax vs oral decitabine/cedazuridine alone in high-risk MDS: a propensity score analysisProgram faculty:
Courtney DiNardo, MD, MSCE
Professor of Medicine
Department of Leukemia
MD Anderson Cancer Center
Houston, TexasBrady L. Stein, MD, MHS
Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, IllinoisEunice S. Wang, MD
Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New YorkResources:
To download the slides associated with this podcast discussion, please visit the program page. -
In this episode, Manali Bhave, MD; Annalise Labatut, PharmD, BCOP; and nurse practitioner Jamie L. Carroll, CNP, APRN, MSN, begin by discussing the landmark EMERALD study that led to FDA approval of elacestrant, the first oral selective estrogen receptor degrader (SERD) for treatment of hormone receptor–positive/HER2-negative metastatic breast cancer. Dr. Bhave also briefly reviews ongoing clinical trials of other oral SERDs for estrogen receptor–positive/HER2-negative metastatic breast cancer.
Next, the panel discusses the possible adverse effects with elacestrant, potential drug–drug interactions, and their personal experiences with managing adverse effects in their patients.
Finally, the discussion turns to methods for promoting treatment adherence and persistence and briefly touches on insurance coverage and affordability, including ways that patients and providers can work together to ensure access to approved oral SERDs.
Presenters:
Manali Bhave, MD
Phase I Medical Director
Assistant Professor
Department of Hematology & Medical Oncology
Winship Cancer Institute
Emory University
Atlanta, GeorgiaAnnalise Labatut, PharmD, BCOP
Oncology Clinical Pharmacy Specialist – Breast Oncology
Emory Healthcare/Winship Cancer Institute
Atlanta, GeorgiaJamie L. Carroll, CNP, APRN, MSN
Assistant Professor of Medical Oncology
Mayo Clinic
Rochester, MinnesotaLink to the full program:
https://bit.ly/3UT5Be8Claim CME Credit:
https://bit.ly/4dBuxhx
-
In this episode, Danielle M. Brander, MD; Deborah Stephens, DO; and Brian Hill, MD, PhD, discuss key aspects of the NCCN CLL guidelines and share strategies for applying these recommendations in your clinical practice to optimize treatment and outcomes. The greater discussion addresses:
Optimal selection of therapy for treatment-naive CLL, including second-generation covalent BTK inhibitorsConsiderations in therapy selection for previously treated CLLNovel strategies for treating CLL
Presenters:
Danielle M. Brander, MD
Assistant Professor of Medicine
Division of Hematologic Malignancies and Cellular Therapy
Duke Cancer Institute
Durham, North CarolinaBrian Hill, MD, PhD
Director, Lymphoid Malignancies Program
Staff Physician, Department of Hematology and Medical Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, OhioDeborah Stephens, DO
Associate Professor
Director of the CLL Program
Lineberger Comprehensive Cancer Center
University of North Carolina
Chapel Hill, North CarolinaContent based on a live and online CME program supported by educational grants from AstraZeneca; BeiGene, Ltd.; and Lilly.
Link to full program including downloadable slides:
https://bit.ly/49YxtSq -
In this episode, Colin C. Pritchard, MD, PhD, a pathologist, and Heather H. Cheng, MD, PhD, a medical oncologist, discuss optimal biomarker testing to guide treatment decisions in advanced prostate cancer, with topics including:
Rationale for targeting PARP in prostate cancer with ARI combinationsStudy design nuances and findings from key randomized phase III clinical trials evaluating combination therapy with a PARP inhibitor and ARI, including PROpel, MAGNITUDE, and TALAPRO-2FDA approvals of combination therapy with a PARP inhibitor and ARI, including a comparison of populations based on mutations Optimal biomarker testing for gene mutations in homologous recombination and mismatch repair pathwaysTips for optimal coordination between pathology and medical oncologyPresenters:
Heather H. Cheng, MD, PhD
Associate Professor
Department of Medicine
Division of Hematology and Oncology
Attending Physician
Department of Genitourinary Medical Oncology
Fred Hutchinson Cancer Center
Seattle, WashingtonColin C. Pritchard, MD, PhD
Co-Director
Genetics and Solid Tumors Laboratory
University of Washington Medical Center
Professor
Department of Laboratory Medicine and Pathology
University of Washington
Seattle, WashingtonContent based on an online CME program supported by an independent educational grant from Pfizer, Inc.
Link to full program:
https://bit.ly/3PFagxb -
In this podcast episode, Sara M. Tolaney, MD, MPH, and Melinda Telli, MD, delve into the critical aspects of the current therapeutic landscape for patients with unresectable or metastatic HER2-low, hormone receptor–positive, and triple-negative breast cancer, including:
Challenges with the pathologic testing for HER2-low expressionOptimal treatment of patients with HER2-low advanced breast cancerRole of TROP-2–targeted therapiesManagement of ADC-associated adverse events to optimize treatment outcomesADCs on the horizon for patients with advanced breast cancerPresenters:
Sara M. Tolaney, MD, MPH
Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MassachusettsMelinda Telli, MD
Professor of Medicine
Stanford University School of Medicine
Director, Breast Cancer Program
Stanford Cancer Institute
Palo Alto, CaliforniaContent based on an online CME program supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.
Link to full program:
https://bit.ly/49WxRBM -
The third and final episode in a 3-part series covers the safety profile of and considerations for managing adverse events associated with HER3-targeted antibody–drug conjugates, including patritumab deruxtecan (HER3-DXd) and others, in the setting of lung cancer.
Presenters in this series include:
Rebecca S. Heist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Medical Oncology
Massachusetts General Hospital
Boston, MassachusettsHelena Yu, MD
Associate Attending
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New YorkSupported by an educational grant from Daiichi Sankyo, Inc.
Link to full program, including a downloadable highlights slideset:
https://bit.ly/48ecElW - Show more
